Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancer

ABSTRACT: Interventions: ETS was defined as 20% or more tumor reduction at 8 weeks. Patients with ETS after 8 weeks from the treatment start date continued FOLFIRI + Cmab as induction to 16 weeks, and switched to FOLFIRI +BV for maintenance of progressive disease. Patients without ETS at 8 weeks immediately switched to FOLFIRI+BV to control progression. FOLFIRI+Cmab induction therapy; Cetuximab: 250mg/m2day1 day1, 8(1cours day1:400mg/m2), CPT-11: 180mg/m2 day1, l-LV: 200mg/m2 day1, 5-FU bolus: 400mg/m2 day1, 5-FU infusion: 2400mg/m2 day1-2 FOLFIRI+BV maintenance therapy; Bevacizumab: 5mg/kg day1, CPT-11: 180mg/m2 day1, l-LV: 200mg/m2 day1, 5-FU bolus: 400mg/m2 day1, 5-FU infusion: 2400mg/m2 day1-2 Primary outcome(s): Progression free survival (PFS) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2638283 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of FOLFIRI+Ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy (RAINCLOUD).RAINCLOUD-TR.

Project description:Interventions: FOLFIRI+Ramucirumab (5-FU(bolus): 400mg/m2 on day1, 5-FU(ci): 2,400mg/m2 on day1-3 (46hr), l-LV: 200mg/m2 on day1, CPT-11: 180mg/m2 on day1, Ramucirumab: 8mg/kg on day1) *Allow dose level -1 (150mg/m2) RAINCLOUD-TR Collecting blood 12mL at the time of before RAINCLOUD protocol treatment, and PD. Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), no treatment control/standard of care control, parallel assignment, treatment purpose

| 2615323 | ecrin-mdr-crc

Safety and efficacy of preoperative chemotherapy with SOX+Cetuximab in patients with liver-only metastases(H2,H3), KRAS-WT from colorectal cancer(KSCC1002)

Project description:Interventions: L-OHP 130mg/m2 i.v. (day1) Cmab 250mg/m2 i.v. (only the first time Cmab 400mg/m2) S-1 80mg/m2 (day1-14) to be repeated every 3 weeks for 4 cycles. Surgery was planned after SOX+Cetuximab therapy. Primary outcome(s): Liver resection rate Study Design: Single arm Non-randomized

| 2619781 | ecrin-mdr-crc

Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)

Project description:Interventions: MetronomicIRIS(S-1/CPT-11)/Cmab combination therapy S-1:50 or 60 or 80mg/body/day(day3-7,10-14,17-21,24-28) CPT-11:60mg/m2(day1,8,15) Cmab*:250mg/m2(day1,8,15,22) *:400mg/m2 for the initial dosing(day1) every 4 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2627425 | ecrin-mdr-crc

Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine(RAINCLOUD)

Project description:Interventions: FOLFIRI+Ramucirumab (5-FU(bolus): 400mg/m2 on day1, 5-FU(ci): 2,400mg/m2 on day1-3 (46hr), l-LV: 200mg/m2 on day1, CPT-11: 180*mg/m2 on day1, Ramucirumab: 8mg/kg on day1) *Allow dose level -1 (150mg/m2) Primary outcome(s): Progression-Free Survival (PFS) Study Design: Single arm Non-randomized

| 2643874 | ecrin-mdr-crc

Evaluation of the reintroducing FOLFOX or XELOX +/- BV in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy.(REACT study)

Project description:Interventions: FOLFOX +/- BV therapy L-OHP:85mg/m2 5-FU(bolus):400mg/m2 l-LV:200mg/m2 5-FU(infusion):2,400mg/m2 +/- BV:5mg/m2 XELOX +/- BV therapy L-OHP:130mg/m2 Cape:2,000mg/day +/- BV:7.5mg/m2 Primary outcome(s): response rate disease control rate Study Design: Single arm Non-randomized

| 2621954 | ecrin-mdr-crc

Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9 -

Project description:Interventions: (SOX+Cmab) L-OHP 85mg/m2 i.v.(day1) Cmab 500mg/m2 i.v.(day1) S-1 80mg/m2(day1-7) to be repeated every 2 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2624365 | ecrin-mdr-crc

A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancer

Project description:Interventions: arm A-1:mFOLFOX6+Bevacizumab Bevacizumab 5mg/kg/bi-week L-OHP 85mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week arm A-2: CapeOX+Bevacizumab Bevacizumab 7.5mg/kg/tri-week L-OHP 130mg/m2/tri-week Capecitabine 1200-2100mg/twice/day(day 1-15) arm B-1:TS-1/CPT-11+Bevacizumab(SIRB) Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week arm B-2:TS-1/CPT-11+Bevacizumab(IRIS/BV) Bevacizumab 5mg/kg/(day1and15)/4-weeks CPT-11 100mg/m2/(day1and15)/4-weeks S-1 40-60mg/twice/day(day1-15)/4weeks Primary outcome(s): Progression free survival(PFS) Study Design: Parallel Randomized

| 2623247 | ecrin-mdr-crc

Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis

Project description:Interventions: day1:CPT-11(150mg/m2),L-OHP(65mg/m2),L-LV(200mg/m2) day1-2:5-FU(3200mg/m2)48hr civ, day1:Panitumumab(6mg/kg) or day1 and 7 cetuximab(400mg/m2) ever 2 weeks Primary outcome(s): R0 rejective rate Study Design: Single arm Non-randomized

| 2620819 | ecrin-mdr-crc

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Project description:This single arm study will assess the efficacy and safety of a combination of modified FOLFIRI (irinotecan, 5-FU and leucovirin), Avastin and cetuximab in patients with previously untreated metastatic colorectal cancer. Patients will receive modified FOLFIRI (irinotecan 180mg/m2 iv, leucovirin 200mg/m2 iv, and 5-FU 400mg/m2 iv) on day 1 of each 2 week cycle, in combination with Avastin (5mg/kg iv on day 1 of each cycle) and cetuximab (loading dose of 400mg/m2 followed by 250mg/m2 on day 3 of each cycle). The anticipated time on study treatment is until disease progression or unacceptable toxicity, and the target sample size is <100 individuals.

| 2047783 | ecrin-mdr-crc

A prospective study comparing targeted anticancer drug + irinotecan and targeted anticancer drug + 5-Fluorouracil / Leucovorin as maintenance treatment after primary induction chemotherapy for metastatic colorectal cancer

Project description:Interventions: Drug : This randomized phase 2 clinical trial aims to evaluate the effect of the Bevacizumab/Cetuximab+Irinotecan group compared to the Bevacizumab/Cetuximab+5-fluorouracil/Leucovorin group as maintenance therapy. Administer according to the recommended dosage regimen or the standard of the local institution Experomental group Bevacizumab or Cetuximab + Irinotecan, control group Bevacizumab or Cetuximab + 5 fluorouracil therapy every 2 weeks Recommended dose for Experomental group : Bevacizumab 5mg kg IV Day1, Cetuximab 500mg/m2 IV Day1 , Irinotecan 180mg/m2 IV Day1 Recommended dose of control group: Bevacizumab 5mg kg IV Day1, Cetuximab 500mg/m2 IV Day1,Leucovorin 400mg/m2 IV Day1, 5-fluorouracil 400mg/m2 IV bolus Day1 , 5-fluorouracil 2,400mg/m2 IV Day1-2 Primary outcome(s): Percentage of patients with progression-free status after secondary chemotherapy at one year from random assignment 1yr-PFS2 rate Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT

| 74818 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data